CNOverview
The FLT3-ITD mutation is one of the common pathogenic mutations in AML (acute myeloid leukemia) and is of great significance in the prognosis of hematological tumors and guidance for targeted therapy. To address this, based on multiplex amplicon sequencing technology and combined with a unique primer design scheme, all regions from intron 13 to exon 15 are incorporated into the target region. Through random amplification, detection sensitivity is enhanced, enabling accurate detection of both known and unknown ITD mutations occurring in exons 14-15.
NPM1 exon 12 is a key molecular marker in hematological tumors (especially acute myeloid leukemia, AML). Its detection can assist in the diagnosis and classification of AML; clarifying the mutation status can determine prognosis (e.g., mutant AML often indicates a specific prognosis) and guide precision therapy, which is crucial for optimizing the diagnosis and treatment strategies of hematological tumors. For this, based on multiplex amplicon sequencing technology and combined with a unique primer design scheme, the entire exon 12 is included in the target region, and amplification with multiple pairs of primers ensures primer working efficiency.
For the above two key variant regions in hematological tumor detection, iGeneTech adopts a multiplex amplicon-based technical scheme, which enables convenient, rapid, and sensitive detection of mutation information. Moreover, primers from both regions can be mixed for use, allowing simultaneous detection.
